CBL Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population generated from the human ovarian carcinoma cell line A2780. This heterogeneous pool provides a loss-of-function model of the CBL gene, facilitating studies of its regulatory roles in epithelial ovarian cancer. The polyclonal format retains diverse genetic disruptions, enabling robust pooled analyses without single-cell clonal bias.
The A2780 host line was established from an untreated patient with ovarian carcinoma and features wild-type p53 and cisplatin sensitivity, making it a well-characterized model for drug sensitivity studies. As an epithelial ovarian cancer line, A2780 is extensively used to evaluate platinum-based chemotherapeutics and serves as a relevant background for dissecting CBL-dependent mechanisms.
CBL encodes an E3 ubiquitin-protein ligase that negatively regulates receptor tyrosine kinase (RTK) signaling. Ligand engagement of receptors such as EGFR or PDGFR recruits CBL via adaptors GRB2 and CRK, leading to CBL-mediated ubiquitination and lysosomal degradation of activated receptors. CBL also functions as an adaptor, interacting with CIN85 and 14-3-3 proteins, and modulates downstream pathways including the MAPK/ERK cascade (via GRB2-SOS-RAS-RAF-MEK-ERK) and PI3K-AKT signaling. It additionally targets non-RTK proteins like SYK and ZAP70 for ubiquitination, and undergoes autoubiquitination to regulate its own activity.
In ovarian cancer, CBL loss can drive aberrant RTK activation, yet the A2780 background with intact p53 and cisplatin sensitivity provides a controlled system to study its tumor-suppressive functions. Disruption of CBL in these cells enables investigation of hyperactivated EGFR and PDGFR signaling, altered MAPK and PI3K pathway dynamics, and changes in response to platinum drugs, linking CBL to mechanisms of chemoresistance and tumor progression.
This polyclonal knockout is suited for ubiquitination and phospho-RTK profiling assays, as well as functional experiments including proliferation, migration, and drug sensitivity testing. Researchers can apply western blotting, immunoprecipitation, and RT-qPCR to confirm CBL disruption and assess its impact on receptor stability. The heterogeneous pool supports pooled screening approaches, reducing clonal variation and enhancing reproducibility in high-throughput studies. For inquiries, contact Ascent Research.
